Abstract
Premature ejaculation (PE) is one of the most common male sexual dysfunctions, characterized by reduced intravaginal ejaculatory latency time (IELT) and self-perceived lack of control over ejaculation. PE can place a substantial burden on the sexual satisfaction of the couple and negatively impact their quality of life. Dapoxetine is a short-acting selective serotonin reuptake inhibitor and the first pharmacotherapy approved for the treatment of men with PE. The pharmacokinetic profile of dapoxetine makes it particularly well-suited for the on-demand treatment of PE. Dapoxetine has been investigated in five randomized, placebo-controlled Phase III trials involving 6081 men with PE. Dapoxetine (30 and 60 mg) significantly increased mean IELT across the trials (p ≤ 0.001 both doses vs placebo) up to 24 weeks. Increases in IELT with dapoxetine were observed in men with baseline IELTs ranging from less than 0.5 to 2.0 min, and were accompanied by improvements in patient-reported outcomes (control, satisfactio...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
